Dr. Harry S. Ojeas, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Puerto Rico School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 294
Licensed in Texas since 1992, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Puerto Rico School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TX license J1472 (first issued 1992; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Houston Healthcare Southeast Pasadena, TX
Medical groups
- Texas Digestive Disease Consultants, PLLC (608 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 294
- Services billed
- 1,360
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 78 | 34 |
| Established patient office or other outpatient visit, 20-29 minutes | 74 | 58 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 57 | 56 |
| New patient office or other outpatient visit, 30-44 minutes | 54 | 54 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 47 | 25 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 41 | 41 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 24 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 20 | 20 |
| New patient office or other outpatient visit, 15-29 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Houston, TX | 501 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Houston, TX | 387 |
| Famotidine Other prescribers in Houston, TX | 337 |
| Linzess (linaclotide) Other prescribers in Houston, TX | 284 |
| Sucralfate Other prescribers in Houston, TX | 265 |
| Dicyclomine Hcl Other prescribers in Houston, TX | 228 |
| Sutab (sod sulf/pot chloride/mag sulf) | 204 |
| Metronidazole Other prescribers in Houston, TX | 145 |
| Pantoprazole Sodium Other prescribers in Houston, TX | 144 |
| Amitriptyline Hcl Other prescribers in Houston, TX | 93 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 131 payments worth $2,662 in total to this clinician.
| AbbVie Inc. | $752 |
|---|---|
| Madrigal Pharmaceuticals | $479 |
| Gilead Sciences, Inc. | $241 |
| Celltrion USA Inc. | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | $189 |
| Janssen Biotech, Inc. | $189 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169 |
| Braintree Laboratories, Inc. | $160 |
| Food and Beverage | $2,662 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 1 companies. The companies reported $67,304 in research payments for these studies, mostly to the institutions running them.
- A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie Inc. · Active, not recruiting · NCT03105102 - M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT03398135 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. - M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease
AbbVie Inc. - M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.